Management of the Roflumilast–Phenytoin Interaction

Interaction Classification

Hepatitis C treatment guidelines designate the co‑administration of phenytoin with CYP3A4‑metabolized drugs such as roflumilast as a “red‑light” contraindication because phenytoin markedly reduces drug exposure. 1

When both roflumilast and phenytoin are indicated, clinicians should substitute non‑enzyme‑inducing anticonvulsants (e.g., levetiracetam, gabapentin, lamotrigine) that have minimal impact on CYP450 activity. [2][1]
Levetiracetam, gabapentin, and lamotrigine are specifically recommended as they do not significantly affect CYP450 enzymes, according to CDC recommendations and pharmacology reviews. [3][4]

For patients with a high risk of exacerbations (≥ 2 moderate or ≥ 1 severe exacerbation in the prior year), escalation to a triple inhaler regimen containing a long‑acting muscarinic antagonist, a long‑acting β₂‑agonist, and an inhaled corticosteroid is advised. [5][6]
Adding macrolide maintenance therapy (e.g., azithromycin) may be appropriate provided there are no concerns about QT‑interval prolongation or additional drug interactions with phenytoin. [5][7]
N‑acetylcysteine can be considered as an adjunctive therapy for patients exhibiting a chronic bronchitic phenotype. [5][8]

If phenytoin must be started in a patient already receiving roflumilast, roflumilast should be discontinued before initiating phenytoin.
Clinicians should monitor for an increase in COPD exacerbations after roflumilast discontinuation and reassess disease control within 2–4 weeks, optimizing alternative maintenance therapies as needed. 5